Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02656810 · ClinicalTrials.gov registry record · Phase 1
A Comparison Study of PF708 and Forteo in Healthy Subjects
A Phase 1 study of Osteoporosis, sponsored by Pfenex.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT02656810: Completed Phase 1 study of Osteoporosis, sponsored by Pfenex.
NCT02656810 is a Phase 1 study of Osteoporosis that has completed, run by Pfenex. The registered enrollment target is 70 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02656810, a Phase 1 study of Osteoporosis, has completed, sponsored by Pfenex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the pharmacokinetics (blood levels) of two teriparatide products, PF708 and Forteo, in healthy subjects.
Conditions Studied
Interventions
- DRUG Teriparatide
Study Locations (1)
Indiana
- Covance Clinical Research Unit - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
What the finished NCT02656810 record still lists
NCT02656810 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which Teriparatide is the first listed.
NCT02656810 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT02656810 about?
NCT02656810 is a clinical study titled "A Comparison Study of PF708 and Forteo in Healthy Subjects". The purpose of this study is to compare the pharmacokinetics (blood levels) of two teriparatide products, PF708 and Forteo, in healthy subjects.
What is the current status of trial NCT02656810?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2015-12. Estimated completion is 2016-07.
What conditions does trial NCT02656810 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT02656810?
The interventions under investigation include: Teriparatide (DRUG).
Who is sponsoring clinical trial NCT02656810?
This trial is sponsored by Pfenex, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02656810 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02656810's enrollment target sits among peer trials
70 45th of 84 higher than 40 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
COMPLETED · Phase 1
-
Patient- and Physician-Based Osteoporosis Education
COMPLETED · Phase 1
-
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
COMPLETED · Phase 1
-
Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study
COMPLETED · Phase 1
-
A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia